DE-QPS-HOLDINGS
QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical trials. Today, QPS announced the expansion of its Miami, Florida Phase I clinical trial capabilities to support the growing needs of sponsors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521634782/en/
New, state of the art, clinical trial unit at QPS Miami in South Miami, Florida USA. (Photo: Business Wire)
QPS announces the grand opening of its newest clinical trials unit in Miami, Florida. This new 21 bed unit will complement the existing 85 bed clinical trials unit currently serving the Biotech and Pharmaceutical community. With this new capacity, QPS is poised to accommodate the rapidly increasing demand for obesity trials, as well as continue to support complex, early phase studies in special populations. QPS has extensive experience in allergies, asthma, cell & gene therapy, CNS, COPD, diabetes, elderly, oncology, pediatrics, rheumatoid arthritis, vaccines, women’s health, and many more therapeutic areas.
“We have expanded our Phase I clinical trial capabilities to better serve the hundreds of companies developing potential new obesity-related drugs. We have completed more than 1,500 Phase I-IV clinical trials for drug candidates and this expansion will enable us to support exponentially more sponsors as they progress compounds through proof of concept and First-in-Human trials to the point of candidate nomination,” said Benjamin Chien, Chairman, President, and CEO, QPS Holdings, LLC.
“Our pipeline is filled with sponsors that need this level of support. The number of First-in-Human studies is rapidly increasing and there are very few sites across the country that can conduct them,” said Jose Marcos, Vice President of Clinical Operations, QPS Miami. “QPS is well-known for its success in First-in-Human studies. We excel at complex and special population Phase I trials, and our enrollment and completion rates are among the best in the industry.”
With the expansion comes an increased focus on quality. “To ensure the quality of our clinical trials is maintained, QPS has hired an additional full-time principal investigator to ensure dedicated, physician-involvement at every stage of our trials,” said Chien. “We now have five full-time principal investigators, and a network of more than 25 board-certified subspecialty physician investigators to support the increased volume of studies in our pipeline.”
Wendy Marquina, MD, American Board of Obesity Medicine certified physician, has joined QPS as a primary investigator dedicated to Phase I trials. She brings Board Certification in Obesity, as well as expertise in internal medicine and women’s health to QPS. Since the discovery of the anti-obesity effects of GLP1 and GIP inhibitors, the number of obesity-related clinical trials has dramatically increased. More than 2,300 clinical studies related to obesity are listed as ongoing on clinical trials.gov, and the number is increasing as more companies join the effort to tackle this serious disease and its related comorbidities.
“We expect this demand for obesity-related studies to continue,” said Marquina. “Obesity trials are specialized and unique. And they are in high demand, particularly for companies that want to find an effective solution to this debilitating disease. The road so far is littered with failures in this space, so there is real excitement in the medical community that there may finally be a pathway to help these patients.”
Supporting this expansion in Miami, QPS has co-located its specialty lab services within its Miami-based clinical site. “In the market, you’ll find CROs that offer clinical services, and then you’ll find specialized labs. At QPS, we now we have the unique combination of clinical services and a specialized lab combined under one roof,” said Chien. “That’s important because many of our studies require lab samples to be processed quickly, in less than eight hours. This is only possible by having the clinical site and specialty lab co-located.”
With this newly expanded facility and additional leadership specializing in obesity, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving the needs of the Biotech and Pharmaceutical industry to support global drug development from preclinical through post-marketing needs.
ABOUT QPS HOLDINGS, LLC
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials and clinical research operations services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email infopr@qps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521634782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirion Partners with IAEA to Enhance Radiation Safety on a Global Scale16.9.2025 23:19:00 CEST | Press release
Partnership Agreement to Strengthen Radiation Detection and Measurement Capabilities at the Terrestrial Environmental Radiochemistry (TERC) Laboratory, Safeguarding the Environment and Promoting Nuclear Safety Mirion (NYSE: MIR), a leading provider of advanced radiation safety solutions, has signed a partnership agreement and practical arrangements with the International Atomic Energy Agency (IAEA), the world’s central intergovernmental forum for scientific and technical cooperation in the nuclear field, to cooperate in the area of radiation detection and measurement. Through this collaboration, Mirion’s advanced instrumentation and profound understanding of ionizing radiation will combine with the IAEA’s expertise and influence to advance the safe and secure use of nuclear technology worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916693003/en/ Mirion Chairman of the Board and CEO Thomas Logan and IAEA Director
NIQ and Displayce Collaborate to Bring Sales Lift Measurement to Europe’s DOOH Advertising Market16.9.2025 18:00:00 CEST | Press release
NIQ, a leading consumer intelligence company, and Displayce, a pioneering specialist technology suite for Out-of-Home advertising, are collaborating to bring advanced measurement capabilities to the European DOOH market. By combining NIQ’s trusted consumer intelligence with data from Displayce’s media activation platform, advertisers can link DOOH campaigns to in-store sales performance — driving transparency and accountability across the DOOH ecosystem. NIQ has long been a trusted source of consumer purchase insights for manufacturers and retailers, capturing the buying behavior of millions of households across more than 90 countries. Now, NIQ is extending its expertise and insights into the media ecosystem, empowering advertisers and agencies with new data assets and measurement solutions to improve their understanding of consumers and drive better ROI. Through the collaboration, NIQ and Displayce are driving the DOOH ecosystem toward more addressable, transparent, and results-driven
Capcom’s Resident Evil Requiem, the Latest Title in the Series, Also Coming to Nintendo Switch 2 on February 27, 2026!16.9.2025 15:00:00 CEST | Press release
– Additionally, two other Resident Evil series titles to be released for the console on the same date in step with Capcom’s multi-platform strategy – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series scheduled for release on February 27, 2026, for PlayStation®5 system, Xbox Series X|S, and PC, will also be released for Nintendo Switch™ 2 at launch. In addition, Resident Evil 7 biohazard and Resident Evil Village, two other titles in the series, will also be released for Nintendo Switch 2 on the same date. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250916064724/en/ Resident Evil Requiem Key Art Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development experience cultivated over numerou
Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production16.9.2025 15:00:00 CEST | Press release
Human insight and autonomous agents work together to transform operations, enhance efficiency, improve safety, and unlock new value across the enterprise. Aker BP, one of Europe's largest independent oil companies, and Cognite, the global leader in industrial AI, deepen their strategic partnership through the expanded adoption of Cognite Atlas AI™,harnessing the power of AI agents to improve efficiency, reduce costs, and elevate productivity. This enhanced collaboration puts Aker BP at the forefront of leveraging agentic AI to drive significant value and transform its operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250903134233/en/ Aker BP Leverages Cognite Atlas AI™ to Pioneer an AI-First Future in Exploration and Production Aker BP's "AI-first strategy" was developed to help lead the energy sector into a data-driven future by seamlessly integrating AI applications within industrial settings and business objectiv
GlobalPlatform to Drive Next Phase of Growth for PSA Certified, Accelerating Security Adoption16.9.2025 15:00:00 CEST | Press release
Founded by Arm and industry partners, PSA Certified will continue to evolve under GlobalPlatform’s governance as the trusted global standard for secure connected devices GlobalPlatform announced today it will assume governance of PSA Certified, the global security certification scheme launched by Arm and key partners in 2019. In this next phase of growth, GlobalPlatform—the global standards organization for secure digital services and devices—will drive further collaboration, broader industry participation, and greater regulatory alignment for PSA Certified. Since its launch, PSA Certified has become a globally adopted framework that helps manufacturers and developers build secure connected products based on a Root of Trust. It aligns key security components—such as device identity, cryptography, attestation, and secure boot—with certification needs, regulatory requirements, and global best practices. To date, more than 250 products — spanning silicon, software, and devices—have been c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom